Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05711940 · ClinicalTrials.gov registry record · Phase 3

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

A Phase 3 study of Treatment-Resistant Depression, sponsored by COMPASS Pathways.

Active
Registry status
Phase 3
Development phase
572
Enrollment target
20
Study locations

NCT05711940 is a Phase 3 study of Treatment-Resistant Depression that is active but no longer recruiting, run by COMPASS Pathways. The registered enrollment target is 572 participants, above the 363-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (58% higher). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05711940, a Phase 3 study of Treatment-Resistant Depression, is active but no longer recruiting, sponsored by COMPASS Pathways.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
572 participants
Enrollment target
20
Study locations

Study Summary

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Conditions Studied

Treatment-Resistant Depression

Interventions

  • DRUG Psilocybin

Study Locations (20)

California

  • Clinical Innovations, Inc. - Bellflower
  • M3 Wake Research - Encino
  • The Regents of the University of California - San Diego - La Jolla
  • Kadima Neuropsychiatry Institute - La Jolla
  • CalNeuro Research Group, Inc - Los Angeles
  • Catalina Research Institute, LLC - Montclair
  • Piedmont Hospital Neuroscience Centre - Oakland
  • ATP Clinical Research, Inc. - Orange
  • CITrials - Riverside
  • Lumos Clinical Research Center - San Jose
  • Syrentis Clinical Research - Santa Ana
  • Stanford University - Stanford
  • ASCLEPES Research Centers - Thousand Oaks
  • Pacific Clinical Research Management Group, LLC - Upland

Florida

  • Innovative Clinical Research, Inc. - Lauderhill
  • Central Miami Medical Institute, LLC - Miami
  • Behavioral Clinical Research, Inc. - Miami Lakes
  • Health Synergy Clinical Research - Okeechobee
  • Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare - Orlando

Arizona

  • Lighthouse Psychiatry Scottsdale - Gilbert

Trial Details

FieldValue
Enrollment Target 572 participants
Start Date 2023-02-14
Est. Completion 2026-12
Phase Phase 3

Sponsor

COMPASS Pathways

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05711940

The ClinicalTrials.gov registry entry for NCT05711940 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 572 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 363-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (58% higher). The listed sponsor is COMPASS Pathways, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.

NCT05711940 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT05711940 about?

NCT05711940 is a clinical study titled "Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD". Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

What is the current status of trial NCT05711940?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 572 participants. The study started on 2023-02-14. Estimated completion is 2026-12.

What conditions does trial NCT05711940 study?

This clinical trial studies the following conditions: Treatment-Resistant Depression.

What interventions are being tested in trial NCT05711940?

The interventions under investigation include: Psilocybin (DRUG).

Who is sponsoring clinical trial NCT05711940?

This trial is sponsored by COMPASS Pathways, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05711940 being conducted?

This trial has 20 study locations across Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Treatment-Resistant Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Treatment-Resistant Depression

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.